In the early part of April, the US Food and Drug Administration (FDA) approved the first skin-patch delivery system for drug that is commonly used to treat attention deficit hyperactivity disorder (ADHD). The drug is methylphenidate, the same active ingredient in Ritalin, a well-know prescription drug in an oral tablet formulation that has been used for many years for children with ADHD. The brand name for the skin patch form of the drug is called Daytrana. The advantage of this new drug is that is designed for once-a-day application. According to news releases, Daytrana will be available in four sizes (10mg, 15mg, 20mg, and 30mg). News reports also indicate that physicians prescribing Daytrana can manage the effect the drug is having and any attending side effects by having their patients wear the patch for shorter periods of time than the recommended 9 hours, on a given day. In clinical trials, wearing the patch for 9 hours provided a therapeutic effect for a full 12 hours. One report indicates that ADHD affects almost 8% of all school-age children.